Yi Luo

Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial

Arun J. Sanyal, Edgar D. Charles, Brent A. Neuschwander‐Tetri et al. · The Lancet · 2018 · 511 citations

Inflammation, Hepatology, Medicine +7

Pegbelfermin (BMS‐986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study

Edgar D. Charles, Brent A. Neuschwander‐Tetri, Juan P. Frías et al. · Obesity · 2018 · 243 citations · Full text

Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial of BMS-986020, a Lysophosphatidic Acid Receptor Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis

Scott M. Palmer, Laurie D. Snyder, Jamie L. Todd et al. · CHEST Journal · 2018 · 202 citations · Full text

Detection, quantification and confirmation of anabolic steroids in equine plasma by liquid chromatography and tandem mass spectrometry

Fuyu Guan, Cornelius E. Uboh, Lawrence R. Soma et al. · Journal of Chromatography B · 2005 · 92 citations

Medicine, Anabolic Steroids, Physiology +9

Collision-induced dissociation pathways of anabolic steroids by electrospray ionization tandem mass spectrometry

Fuyu Guan, Lawrence R. Soma, Yi Luo et al. · Journal of the American Society for Mass Spectrometry · 2006 · 82 citations

Engineering, Secondary Metabolite, Organic Chemistry +16